OC
CRNX icon

Oppenheimer & Co’s Crinetics Pharmaceuticals CRNX Stock Holding History

Oppenheimer & Co’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,973
Closed -$278K – 1714
2025
Q4 		$278K Buy
5,973
+776
+15% +$34.5K ﹤0.01% 1298
2025
Q3 		$216K Buy
+5,197
New +$166K ﹤0.01% 1510
2025
Q1 		– Sell
-5,444
Closed -$278K – 1589
2024
Q4 		$278K Sell
5,444
-25
-0.5% -$1.4K ﹤0.01% 1303
2024
Q3 		$279K Buy
5,469
+770
+16% +$39.7K ﹤0.01% 1276
2024
Q2 		$210K Buy
4,699
+25
+0.5% +$1.16K ﹤0.01% 1323
2024
Q1 		$219K Buy
+4,674
New +$183K ﹤0.01% 1303

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Oppenheimer & Co's CRNX Position: Q1 2026 in Review

Oppenheimer & Co sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2026, closing a stake of 5,973 shares — an estimated $278K sold.

Oppenheimer & Co first reported a position in CRNX in Q1 2024 and held it in 6 quarters. The position peaked at $279K in Q3 2024. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Oppenheimer & Co reported no remaining Crinetics Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Oppenheimer & Co sold 5,973 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $278K.
  • Oppenheimer & Co first reported a position in Crinetics Pharmaceuticals in Q1 2024 and held it in 6 quarters.
  • Oppenheimer & Co's Crinetics Pharmaceuticals position peaked at $279K in Q3 2024.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Oppenheimer & Co's 13F filing for Q1 2026, filed 24 Apr 2026.